KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will acquire KalVista for $27 per share in cash. Investors are watching deal closing risks and regulatory approvals. Trading volume reached 69.4 million shares, about 3,323% above its three-month average of 2 million shares. KalVista Pharmaceuticals IPO’d in 2015 and has fallen 66% since going public.
How the markets moved today
The S&P 500 slipped 0.02% to finish Wednesday at 7,138, while the Nasdaq Composite inched up 0.04% to close at 24,673. Within the biotechnology sector, rivals were mixed, with Prothena closing at $10.87, down 5.56%, as investors reassessed risk around drug pipelines and deal activity.
What this means for investors
KalVista Pharmaceuticals’ stock is pricing in a high likelihood that the company will be taken private by Italy’s Chiesi Group at $27 per share, after its share price spiked 39% today to $26.67. Home to EKTERLY, an oral medicine for hereditary angioedema, which affects 1 in 50,000 people, KalVista’s addition to Chiesi will round out the latter’s portfolio of rare disease treatments.
The acquisition is interesting to me because KalVista was previously one of the most-shorted stocks on the market, with 40% short interest. With EKTERLY only recently being approved in July 2025 — and KalVista only reporting three quarters of revenue from the treatment — Chiesi’s larger, international scale should help the nascent treatment option reach more potential patients.
Should you buy stock in KalVista Pharmaceuticals right now?
Before you buy stock in KalVista Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and KalVista Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $497,606!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,306,846!*
Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 200% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
